Jaguar Health, Inc. - JAGX STOCK NEWS

Jaguar Health (NASDAQ:JAGX) announced an investor webcast scheduled for September 20, 2021, at 8:30 AM Eastern Time. The company is also launching an educational awareness contest in honor of Indigenous Peoples' Day on October 11, 2021. This fifth contest aims to honor Indigenous healers and will award a winner a book on ethnobotany. Participants must submit answers to multiple-choice questions by 9:00 AM on the contest date. Jaguar Health focuses on developing plant-based pharmaceuticals for gastrointestinal issues.

Jaguar Health (NASDAQ:JAGX) announced that the European Medicines Agency (EMA) has accepted the orphan drug designation application for crofelemer for treating short bowel syndrome with intestinal failure (SBS-IF). This acceptance initiates a formal review process by the EMA's Committee for Orphan Medicinal Products. The company aims to secure conditional marketing authorization in Europe, focusing on this critical orphan disease. Crofelemer, previously designated as an orphan drug by the FDA for SBS in the U.S., has significant market potential, especially given that approximately 10,000 to 20,000 patients may be affected in both the U.S. and Europe.

Jaguar Health (NASDAQ:JAGX) has successfully completed a $776,200 private placement of approximately 309,242 shares of Common Stock. This offering, led by impact investor Josh Mailman and including Jaguar's CEO and CFO, was priced at a premium to market. The company's subsidiary, Napo EU, aims to expand access to its drug crofelemer in Europe, specifically targeting short bowel syndrome. A merger with Dragon SPAC is pending regulatory approval, expected by early October 2021. Ismaila Sougoufara has been promoted to Senior Director, Corporate Controller.

Jaguar Health has appointed Karen J. Brunke, Ph.D., as Executive VP of Corporate and Business Development and Chip Whitlow as Marketing Director. These appointments underscore the company's commitment to advancing crofelemer for treating chemotherapy-induced diarrhea (CID) in dogs, with expected approval in Q4 2021. The appointments aim to foster partnerships for crofelemer's potential human applications and enhance the ongoing commercialization efforts. With an increase in canine cancer diagnoses, these developments signify an important market opportunity for Jaguar.

Jaguar Health, Inc. (NASDAQ:JAGX) announced a 1-for-3 reverse stock split of its common stock, effective September 8, 2021. This decision follows approval from a majority of shareholders at a special meeting held in December 2020. The reverse split aims to align Jaguar's stock price with institutional investing standards, enhancing its appeal to long-term investors. Post-split, every three shares will convert to one, and fractional shares will be compensated with cash. Jaguar continues its focus on developing plant-based non-opioid medicines for gastrointestinal issues.

Jaguar Health, Inc. (NASDAQ:JAGX) announced the voting results from its Annual Meeting of Stockholders held on September 3, 2021. Proposals 1, 2, 4, 5, and 6 were approved, including the election of a director and the ratification of the accounting firm. However, Proposal 3 to increase authorized common stock from 150 million to 290 million shares failed to pass, despite over 75% of votes in favor. The stockholders chose to hold advisory votes on executive compensation every three years. More details are available in the proxy statement filed with the SEC.

Jaguar Health announced its subsidiary, Napo Pharmaceuticals, submitted an abstract for a clinical study on the effects of crofelemer (Mytesi) on the gut microbiome in HIV/AIDS patients for IDWeek 2021.

The study investigates how crofelemer impacts microbiota in people living with HIV/AIDS undergoing antiretroviral therapy. Mytesi is FDA-approved for treating noninfectious diarrhea in these patients. The findings could provide insights into gut health and inflammation related to HIV.

Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), signed a license agreement with its Italian subsidiary, Napo EU S.p.A., for the development and commercialization of crofelemer and lechlemer in Europe. Napo will receive an upfront payment of $10 million and potential milestone payments. The initial focus is on securing accelerated conditional approval for short bowel syndrome with intestinal failure. Napo EU also plans to explore further indications, contingent on additional payments and funding.

Jaguar Health's subsidiary, Napo Pharmaceuticals, announced the completion of a preclinical toxicology study for lechlemer (NP-300), targeting diarrhea relief from cholera and other infections. Supported by the National Institute of Allergy and Infectious Diseases, this study is crucial for filing an Investigational New Drug (IND) application in early 2022. Lechlemer is derived from Croton lechleri and aims to provide cost-effective treatment, particularly for neglected diseases. The company continues to conduct additional necessary studies for the IND application.